156 related articles for article (PubMed ID: 12187327)
21. A novel method to load topotecan into liposomes driven by a transmembrane NH₄EDTA gradient.
Yang Y; Ma Y; Wang S
Eur J Pharm Biopharm; 2012 Feb; 80(2):332-9. PubMed ID: 22041601
[TBL] [Abstract][Full Text] [Related]
22. Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
Int J Pharm; 2010 Oct; 399(1-2):31-6. PubMed ID: 20678563
[TBL] [Abstract][Full Text] [Related]
23. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.
Serwer LP; Noble CO; Michaud K; Drummond DC; Kirpotin DB; Ozawa T; Prados MD; Park JW; James CD
Neuro Oncol; 2011 Dec; 13(12):1288-95. PubMed ID: 21954443
[TBL] [Abstract][Full Text] [Related]
24. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine.
Burke TG; Gao X
J Pharm Sci; 1994 Jul; 83(7):967-9. PubMed ID: 7965676
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
26. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
[TBL] [Abstract][Full Text] [Related]
27. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
Saito R; Krauze MT; Noble CO; Drummond DC; Kirpotin DB; Berger MS; Park JW; Bankiewicz KS
Neuro Oncol; 2006 Jul; 8(3):205-14. PubMed ID: 16723630
[TBL] [Abstract][Full Text] [Related]
28. The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.
Fugit KD; Anderson BD
J Control Release; 2014 Jan; 174():88-97. PubMed ID: 24231406
[TBL] [Abstract][Full Text] [Related]
29. Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.
Grahn AY; Bankiewicz KS; Dugich-Djordjevic M; Bringas JR; Hadaczek P; Johnson GA; Eastman S; Luz M
J Neurooncol; 2009 Nov; 95(2):185-197. PubMed ID: 19466380
[TBL] [Abstract][Full Text] [Related]
30. Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers.
Venâncio JH; Andrade LM; Esteves NLS; Brito LB; Valadares MC; Oliveira GAR; Lima EM; Marreto RN; Gratieri T; Taveira SF
J Pharm Pharmacol; 2017 Oct; 69(10):1318-1326. PubMed ID: 28703281
[TBL] [Abstract][Full Text] [Related]
31. Optimization of liposomal topotecan for use in treating neuroblastoma.
Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB
Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814
[TBL] [Abstract][Full Text] [Related]
32. The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate.
Yang W; Yang Z; Fu J; Guo M; Sun B; Wei W; Liu D; Liu H
Biomater Sci; 2018 Dec; 7(1):419-428. PubMed ID: 30500018
[TBL] [Abstract][Full Text] [Related]
33. A Novel Polymer-Lipid Hybrid Nanoparticle for the Improvement of Topotecan Hydrochloride Physicochemical Properties.
Silva EJ; Souza LG; Silva LAD; Taveira SF; Guilger RC; Liao LM; Queiroz Junior LHK; Santana MJ; Marreto RN
Curr Drug Deliv; 2018; 15(7):979-986. PubMed ID: 29243576
[TBL] [Abstract][Full Text] [Related]
34. Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.
Pinel S; Chastagner P; Merlin JL; Marchal C; Taghian A; Barberi-Heyob M
J Neurooncol; 2006 Jan; 76(1):31-8. PubMed ID: 16311843
[TBL] [Abstract][Full Text] [Related]
35. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
36. Ion-Pairing Contribution to the Liposomal Transport of Topotecan as Revealed by Mechanistic Modeling.
Fugit KD; Anderson BD
J Pharm Sci; 2017 Apr; 106(4):1149-1161. PubMed ID: 28007561
[TBL] [Abstract][Full Text] [Related]
37. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design.
Vali AM; Toliyat T; Shafaghi B; Dadashzadeh S
Drug Dev Ind Pharm; 2008 Jan; 34(1):10-23. PubMed ID: 18214751
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel.
Chang G; Ci T; Yu L; Ding J
J Control Release; 2011 Nov; 156(1):21-7. PubMed ID: 21777632
[TBL] [Abstract][Full Text] [Related]
39. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
40. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]